Effects of IGF-I in HIV Metabolic Disease

Exclusion Criteria

• •Two consecutive viral \>75 or \> 50 copies/mL using the tests listed above
• •Presence of AIDS wasting
• •Change in antiretroviral medication (not dose) in the prior 3 months
• •Coronary artery disease, cerebrovascular, or peripheral arterial disease
• •Diabetes mellitus
• •Adrenal insufficiency, hypoglycemia, thyroid disease, or other endocrine disorder that is untreated
• •Malignancy
• •Eating disorder
• •Pregnancy (urine pregnancy test is required of all females)
• •Previous liposuction or bariatric surgery
• •Other systemic conditions or other disorders at the discretion of the investigators
• •Current use of systemic glucocorticoids, or other agent affecting body weight or glucose homeostasis or other drug at the discretion of the investigators
• •Use of interferon within the past six months
• •Use of insulin, insulin secretagogue, thiazolidinedione, or metformin in the prior 3 months
• •Initiation or dose adjustment, within the prior 3 months, of any of the following drugs or drug classes: fibrate, cholesterol binding resin, statin, niacin, or omega 3 fatty acid (fish oil).
• •Use of uridine, growth hormone, IGF-I, and growth hormone releasing factor analogues